Canada

Canada

Hepatitis B

Download HBV data

Prevalence of chronic HBV (HBsAg+)

National
Download
Value (%) Year Type Source
2.22 (1.71 - 2.81) 2015 Modelled WHO
0.6 (0.40 - 1.10) 2016 Modelled Razavi-Shearer et al, 2018
0.76 (0.74 - 0.79) 2013 Modelled Schweitzer et al, 2015
1.71 (1.57 - 1.87) 2019 Modelled IHME, GBD 2019 (accessed 2020)
1.9 (1.74 - 2.06) 2018 Modelled IHME, GBD 2019 (accessed 2022)
1.91 (1.75 - 2.08) 2017 Modelled IHME, GBD 2019 (accessed 2022)
1.92 (1.77 - 2.09) 2016 Modelled IHME, GBD 2019 (accessed 2022)
1.94 (1.77 - 2.11) 2015 Modelled IHME, GBD 2019 (accessed 2022)
1.95 (1.79 - 2.12) 2014 Modelled IHME, GBD 2019 (accessed 2022)
1.95 (1.80 - 2.12) 2013 Modelled IHME, GBD 2019 (accessed 2022)
1.96 (1.80 - 2.12) 2012 Modelled IHME, GBD 2019 (accessed 2022)
1.97 (1.80 - 2.13) 2011 Modelled IHME, GBD 2019 (accessed 2022)
1.98 (1.80 - 2.15) 2010 Modelled IHME, GBD 2019 (accessed 2022)
1.98 (1.81 - 2.15) 2009 Modelled IHME, GBD 2019 (accessed 2022)
1.99 (1.82 - 2.15) 2008 Modelled IHME, GBD 2019 (accessed 2022)
2 (1.83 - 2.16) 2007 Modelled IHME, GBD 2019 (accessed 2022)
2.01 (1.84 - 2.18) 2006 Modelled IHME, GBD 2019 (accessed 2022)
2.02 (1.84 - 2.20) 2005 Modelled IHME, GBD 2019 (accessed 2022)
2.03 (1.85 - 2.19) 2004 Modelled IHME, GBD 2019 (accessed 2022)
2.03 (1.86 - 2.20) 2003 Modelled IHME, GBD 2019 (accessed 2022)
2.04 (1.88 - 2.21) 2002 Modelled IHME, GBD 2019 (accessed 2022)
2.05 (1.89 - 2.23) 2001 Modelled IHME, GBD 2019 (accessed 2022)
2.06 (1.90 - 2.25) 2000 Modelled IHME, GBD 2019 (accessed 2022)
2.07 (1.91 - 2.26) 1999 Modelled IHME, GBD 2019 (accessed 2022)
2.09 (1.93 - 2.28) 1998 Modelled IHME, GBD 2019 (accessed 2022)
2.1 (1.94 - 2.29) 1997 Modelled IHME, GBD 2019 (accessed 2022)
2.11 (1.95 - 2.31) 1996 Modelled IHME, GBD 2019 (accessed 2022)
2.12 (1.94 - 2.32) 1995 Modelled IHME, GBD 2019 (accessed 2022)
2.13 (1.95 - 2.33) 1994 Modelled IHME, GBD 2019 (accessed 2022)
2.14 (1.96 - 2.34) 1993 Modelled IHME, GBD 2019 (accessed 2022)
2.15 (1.97 - 2.35) 1992 Modelled IHME, GBD 2019 (accessed 2022)
2.15 (1.97 - 2.35) 1991 Modelled IHME, GBD 2019 (accessed 2022)
2.16 (1.97 - 2.36) 1990 Modelled IHME, GBD 2019 (accessed 2022)
1.89 (1.72 - 2.06) 2019 Modelled IHME, GBD 2019 (accessed 2022)
Showing out of
Show more
Children under-5 years
Download
Value (%) Year Type Source
1.03 (0.72 - 1.42) 2015 Modelled WHO
0.27 (0.20 - 0.34) 2019 Modelled IHME, GBD 2019 (accessed 2020)
0.43 (0.32 - 0.57) 2019 Modelled IHME, GBD 2019 (accessed 2022)
0.46 (0.35 - 0.60) 2018 Modelled IHME, GBD 2019 (accessed 2022)
0.49 (0.37 - 0.63) 2017 Modelled IHME, GBD 2019 (accessed 2022)
0.51 (0.38 - 0.66) 2016 Modelled IHME, GBD 2019 (accessed 2022)
0.53 (0.40 - 0.69) 2015 Modelled IHME, GBD 2019 (accessed 2022)
0.57 (0.42 - 0.73) 2014 Modelled IHME, GBD 2019 (accessed 2022)
0.6 (0.45 - 0.78) 2013 Modelled IHME, GBD 2019 (accessed 2022)
0.65 (0.49 - 0.84) 2012 Modelled IHME, GBD 2019 (accessed 2022)
0.69 (0.52 - 0.90) 2011 Modelled IHME, GBD 2019 (accessed 2022)
0.74 (0.56 - 0.98) 2010 Modelled IHME, GBD 2019 (accessed 2022)
0.81 (0.61 - 1.06) 2009 Modelled IHME, GBD 2019 (accessed 2022)
0.9 (0.68 - 1.16) 2008 Modelled IHME, GBD 2019 (accessed 2022)
0.98 (0.75 - 1.28) 2007 Modelled IHME, GBD 2019 (accessed 2022)
1.06 (0.81 - 1.39) 2006 Modelled IHME, GBD 2019 (accessed 2022)
1.1 (0.84 - 1.45) 2005 Modelled IHME, GBD 2019 (accessed 2022)
1.13 (0.86 - 1.46) 2004 Modelled IHME, GBD 2019 (accessed 2022)
1.15 (0.88 - 1.47) 2003 Modelled IHME, GBD 2019 (accessed 2022)
1.17 (0.90 - 1.48) 2002 Modelled IHME, GBD 2019 (accessed 2022)
1.18 (0.90 - 1.50) 2001 Modelled IHME, GBD 2019 (accessed 2022)
1.2 (0.91 - 1.54) 2000 Modelled IHME, GBD 2019 (accessed 2022)
1.21 (0.93 - 1.55) 1999 Modelled IHME, GBD 2019 (accessed 2022)
1.23 (0.94 - 1.57) 1998 Modelled IHME, GBD 2019 (accessed 2022)
1.25 (0.95 - 1.59) 1997 Modelled IHME, GBD 2019 (accessed 2022)
1.26 (0.96 - 1.62) 1996 Modelled IHME, GBD 2019 (accessed 2022)
1.28 (0.96 - 1.66) 1995 Modelled IHME, GBD 2019 (accessed 2022)
1.29 (0.97 - 1.66) 1994 Modelled IHME, GBD 2019 (accessed 2022)
1.3 (0.98 - 1.68) 1993 Modelled IHME, GBD 2019 (accessed 2022)
1.31 (0.99 - 1.69) 1992 Modelled IHME, GBD 2019 (accessed 2022)
1.32 (1 - 1.71) 1991 Modelled IHME, GBD 2019 (accessed 2022)
1.34 (1 - 1.74) 1990 Modelled IHME, GBD 2019 (accessed 2022)
0.34 (0.29 - 0.39) 2020 Modelled WHO
Showing out of
Show more
Technical notes

Number of people living with chronic HBV

National
Download
Value Year Type Source
230,000 (145,000 - 383,000) 2016 Modelled Razavi-Shearer et al, 2018
42,800 2011 Survey/reported Rotermann A et al.
180,800 2011 Survey/reported Rotermann A et al.
625,023 (571,682 - 682,382) 2019 Modelled IHME, GBD 2019 (accessed 2020)
646,893 (591,431 - 706,116) 2019 Modelled IHME, GBD 2019 (accessed 2022)
645,874 (594,228 - 700,957) 2018 Modelled IHME, GBD 2019 (accessed 2022)
643,525 (590,520 - 702,841) 2017 Modelled IHME, GBD 2019 (accessed 2022)
642,712 (591,429 - 698,726) 2016 Modelled IHME, GBD 2019 (accessed 2022)
642,024 (588,565 - 698,834) 2015 Modelled IHME, GBD 2019 (accessed 2022)
638,853 (586,000 - 694,579) 2014 Modelled IHME, GBD 2019 (accessed 2022)
635,711 (583,373 - 688,728) 2013 Modelled IHME, GBD 2019 (accessed 2022)
632,300 (580,204 - 683,717) 2012 Modelled IHME, GBD 2019 (accessed 2022)
628,370 (575,171 - 681,137) 2011 Modelled IHME, GBD 2019 (accessed 2022)
623,665 (567,826 - 676,085) 2010 Modelled IHME, GBD 2019 (accessed 2022)
618,628 (564,087 - 669,616) 2009 Modelled IHME, GBD 2019 (accessed 2022)
613,791 (560,963 - 664,058) 2008 Modelled IHME, GBD 2019 (accessed 2022)
609,052 (557,537 - 657,691) 2007 Modelled IHME, GBD 2019 (accessed 2022)
604,313 (552,376 - 655,530) 2006 Modelled IHME, GBD 2019 (accessed 2022)
599,546 (548,384 - 651,564) 2005 Modelled IHME, GBD 2019 (accessed 2022)
595,124 (543,296 - 644,052) 2004 Modelled IHME, GBD 2019 (accessed 2022)
591,388 (543,069 - 639,533) 2003 Modelled IHME, GBD 2019 (accessed 2022)
588,145 (542,481 - 635,685) 2002 Modelled IHME, GBD 2019 (accessed 2022)
585,214 (539,988 - 632,889) 2001 Modelled IHME, GBD 2019 (accessed 2022)
582,466 (536,200 - 634,396) 2000 Modelled IHME, GBD 2019 (accessed 2022)
580,272 (534,351 - 631,388) 1999 Modelled IHME, GBD 2019 (accessed 2022)
578,778 (533,327 - 629,136) 1998 Modelled IHME, GBD 2019 (accessed 2022)
577,311 (532,397 - 628,779) 1997 Modelled IHME, GBD 2019 (accessed 2022)
575,204 (528,735 - 627,056) 1996 Modelled IHME, GBD 2019 (accessed 2022)
571,865 (523,721 - 624,333) 1995 Modelled IHME, GBD 2019 (accessed 2022)
567,509 (519,740 - 618,993) 1994 Modelled IHME, GBD 2019 (accessed 2022)
562,682 (515,494 - 615,838) 1993 Modelled IHME, GBD 2019 (accessed 2022)
557,251 (510,547 - 608,229) 1992 Modelled IHME, GBD 2019 (accessed 2022)
551,100 (504,589 - 601,704) 1991 Modelled IHME, GBD 2019 (accessed 2022)
544,186 (496,216 - 595,804) 1990 Modelled IHME, GBD 2019 (accessed 2022)
Showing out of
Show more

Number of new cases of HBV

National
Download
Value Year Type Source
4,783 2018 Survey/reported Public Health Agency of Canada: Surveillance Report 2018

HBV-related death rate

National
Download
Value (per 100,000) Year Type Source
1.22 (0.91 - 1.58) 2019 Modelled IHME, GBD 2019 (accessed 2020)
0.72 (0.55 - 0.95) 1990 Modelled IHME, GBD 2019 (accessed 2022)
0.74 (0.56 - 0.97) 1991 Modelled IHME, GBD 2019 (accessed 2022)
0.77 (0.58 - 1.01) 1992 Modelled IHME, GBD 2019 (accessed 2022)
0.8 (0.61 - 1.04) 1993 Modelled IHME, GBD 2019 (accessed 2022)
0.83 (0.63 - 1.06) 1994 Modelled IHME, GBD 2019 (accessed 2022)
0.84 (0.64 - 1.10) 1995 Modelled IHME, GBD 2019 (accessed 2022)
0.86 (0.66 - 1.11) 1997 Modelled IHME, GBD 2019 (accessed 2022)
0.85 (0.65 - 1.10) 1996 Modelled IHME, GBD 2019 (accessed 2022)
0.88 (0.67 - 1.14) 1998 Modelled IHME, GBD 2019 (accessed 2022)
0.9 (0.68 - 1.16) 1999 Modelled IHME, GBD 2019 (accessed 2022)
0.91 (0.69 - 1.17) 2000 Modelled IHME, GBD 2019 (accessed 2022)
0.95 (0.72 - 1.22) 2002 Modelled IHME, GBD 2019 (accessed 2022)
0.93 (0.70 - 1.19) 2001 Modelled IHME, GBD 2019 (accessed 2022)
0.97 (0.73 - 1.25) 2003 Modelled IHME, GBD 2019 (accessed 2022)
0.99 (0.74 - 1.28) 2004 Modelled IHME, GBD 2019 (accessed 2022)
1.02 (0.77 - 1.33) 2005 Modelled IHME, GBD 2019 (accessed 2022)
1.04 (0.79 - 1.35) 2006 Modelled IHME, GBD 2019 (accessed 2022)
1.08 (0.82 - 1.41) 2007 Modelled IHME, GBD 2019 (accessed 2022)
1.11 (0.84 - 1.44) 2008 Modelled IHME, GBD 2019 (accessed 2022)
1.12 (0.85 - 1.46) 2009 Modelled IHME, GBD 2019 (accessed 2022)
1.15 (0.86 - 1.50) 2010 Modelled IHME, GBD 2019 (accessed 2022)
1.16 (0.88 - 1.51) 2011 Modelled IHME, GBD 2019 (accessed 2022)
1.2 (0.91 - 1.55) 2012 Modelled IHME, GBD 2019 (accessed 2022)
1.23 (0.93 - 1.58) 2013 Modelled IHME, GBD 2019 (accessed 2022)
1.26 (0.95 - 1.62) 2014 Modelled IHME, GBD 2019 (accessed 2022)
1.27 (0.95 - 1.66) 2016 Modelled IHME, GBD 2019 (accessed 2022)
1.26 (0.94 - 1.64) 2017 Modelled IHME, GBD 2019 (accessed 2022)
1.27 (0.96 - 1.65) 2015 Modelled IHME, GBD 2019 (accessed 2022)
1.22 (0.91 - 1.58) 2019 Modelled IHME, GBD 2019 (accessed 2022)
1.25 (0.94 - 1.63) 2018 Modelled IHME, GBD 2019 (accessed 2022)
Showing out of
Show more
Technical notes

HBV-related deaths

National
Download
Value Year Type Source
833 2016 Modelled WHO
197 (149 - 259) 1990 Modelled IHME, GBD 2019 (accessed 2022)
206 (156 - 269) 1991 Modelled IHME, GBD 2019 (accessed 2022)
215 (164 - 282) 1992 Modelled IHME, GBD 2019 (accessed 2022)
228 (173 - 295) 1993 Modelled IHME, GBD 2019 (accessed 2022)
237 (180 - 306) 1994 Modelled IHME, GBD 2019 (accessed 2022)
249 (189 - 323) 1996 Modelled IHME, GBD 2019 (accessed 2022)
245 (185 - 318) 1995 Modelled IHME, GBD 2019 (accessed 2022)
255 (194 - 329) 1997 Modelled IHME, GBD 2019 (accessed 2022)
264 (201 - 341) 1998 Modelled IHME, GBD 2019 (accessed 2022)
270 (206 - 348) 1999 Modelled IHME, GBD 2019 (accessed 2022)
276 (209 - 355) 2000 Modelled IHME, GBD 2019 (accessed 2022)
294 (222 - 377) 2002 Modelled IHME, GBD 2019 (accessed 2022)
303 (228 - 390) 2003 Modelled IHME, GBD 2019 (accessed 2022)
284 (215 - 365) 2001 Modelled IHME, GBD 2019 (accessed 2022)
310 (232 - 402) 2004 Modelled IHME, GBD 2019 (accessed 2022)
325 (246 - 421) 2005 Modelled IHME, GBD 2019 (accessed 2022)
335 (253 - 433) 2006 Modelled IHME, GBD 2019 (accessed 2022)
351 (265 - 457) 2007 Modelled IHME, GBD 2019 (accessed 2022)
373 (281 - 485) 2009 Modelled IHME, GBD 2019 (accessed 2022)
364 (275 - 472) 2008 Modelled IHME, GBD 2019 (accessed 2022)
394 (298 - 514) 2011 Modelled IHME, GBD 2019 (accessed 2022)
385 (289 - 503) 2010 Modelled IHME, GBD 2019 (accessed 2022)
411 (311 - 533) 2012 Modelled IHME, GBD 2019 (accessed 2022)
425 (322 - 548) 2013 Modelled IHME, GBD 2019 (accessed 2022)
452 (340 - 591) 2016 Modelled IHME, GBD 2019 (accessed 2022)
450 (340 - 583) 2015 Modelled IHME, GBD 2019 (accessed 2022)
440 (334 - 568) 2014 Modelled IHME, GBD 2019 (accessed 2022)
452 (338 - 590) 2017 Modelled IHME, GBD 2019 (accessed 2022)
455 (339 - 590) 2018 Modelled IHME, GBD 2019 (accessed 2022)
445 (332 - 575) 2019 Modelled IHME, GBD 2019 (accessed 2022)
445 (332 - 575) 2019 Modelled IHME, GBD 2019 (accessed 2020)
Showing out of
Show more
Technical notes

Percent of liver cancer deaths attributable to HBV

National
Download
Value (%) Year Type Source
3 (2 - 4) 1990 Modelled IHME, GBD 2019 (accessed 2022)
3 (2 - 4) 1991 Modelled IHME, GBD 2019 (accessed 2022)
3 (2 - 4) 1992 Modelled IHME, GBD 2019 (accessed 2022)
3 (2 - 4) 1994 Modelled IHME, GBD 2019 (accessed 2022)
3 (2 - 4) 1993 Modelled IHME, GBD 2019 (accessed 2022)
3 (2 - 4) 1995 Modelled IHME, GBD 2019 (accessed 2022)
3 (2 - 4) 1996 Modelled IHME, GBD 2019 (accessed 2022)
3 (2 - 5) 1998 Modelled IHME, GBD 2019 (accessed 2022)
3 (2 - 5) 1997 Modelled IHME, GBD 2019 (accessed 2022)
3 (2 - 5) 1999 Modelled IHME, GBD 2019 (accessed 2022)
4 (3 - 5) 2000 Modelled IHME, GBD 2019 (accessed 2022)
4 (2 - 5) 2003 Modelled IHME, GBD 2019 (accessed 2022)
4 (3 - 5) 2002 Modelled IHME, GBD 2019 (accessed 2022)
4 (3 - 5) 2001 Modelled IHME, GBD 2019 (accessed 2022)
4 (3 - 5) 2004 Modelled IHME, GBD 2019 (accessed 2022)
4 (3 - 6) 2005 Modelled IHME, GBD 2019 (accessed 2022)
5 (3 - 7) 2007 Modelled IHME, GBD 2019 (accessed 2022)
4 (3 - 6) 2006 Modelled IHME, GBD 2019 (accessed 2022)
5 (3 - 7) 2009 Modelled IHME, GBD 2019 (accessed 2022)
5 (3 - 7) 2008 Modelled IHME, GBD 2019 (accessed 2022)
5 (4 - 8) 2010 Modelled IHME, GBD 2019 (accessed 2022)
6 (4 - 8) 2011 Modelled IHME, GBD 2019 (accessed 2022)
6 (4 - 9) 2012 Modelled IHME, GBD 2019 (accessed 2022)
6 (4 - 9) 2013 Modelled IHME, GBD 2019 (accessed 2022)
6 (4 - 9) 2014 Modelled IHME, GBD 2019 (accessed 2022)
7 (4 - 10) 2015 Modelled IHME, GBD 2019 (accessed 2022)
6 (4 - 10) 2017 Modelled IHME, GBD 2019 (accessed 2022)
6 (4 - 10) 2016 Modelled IHME, GBD 2019 (accessed 2022)
6 (4 - 9) 2018 Modelled IHME, GBD 2019 (accessed 2022)
6 (4 - 9) 2019 Modelled IHME, GBD 2019 (accessed 2022)
6 (4 - 10) 2019 Modelled IHME, GBD 2019 (accessed 2020)
Showing out of
Show more
Technical notes

Coverage of 3-dose hepatitis B vaccine

Infants
Download
Value (%) Year Type Source
74 2019 Survey/reported WHO/UNICEF
84 2020 Survey/reported WHO/UNICEF
84 2021 Survey/reported WHO/UNICEF
Showing out of
Show more
Technical notes

Number of needles/syringes per PWID per year

National
Download
Value Year Type Source
261 (136 - 883) 2016 Survey/reported The Canadian Network on Hepatitis C Blueprint Writing Committee and Working Groups
People who inject drugs (PWID)
Download
Value Year Type Source
148 (129 - 174) 2015 Survey/reported Larney S et al, 2017
Technical notes
HBV National Action Plan
Source:
HBV elimination goal
Source:
Year of HBV elimination goal
2030
Source:
National prevalence survey within the last 5 years
Not Adopted
Estimates of economic burden
Adopted
Tian F et al
System for monitoring testing and treatment
Not Adopted
Georgetown HIV Policy Lab
HepB birth dose policy
Partially Adopted
Coffin CS, et al
Recommendations for HBV testing of pregnant women
Adopted
National Advisory Committee on Immunization
Eligible for HBV generic medicines
Licensed point-of-care PCR testing to detect HBV
Not Adopted
Health Canada
HBV testing policy
Risk-based
Coffin C et al
HBV testing recommendations for key population (i.e. migrants, foreign-born, etc)
Adopted
Coffin C et al
National treatment guidelines exist
Adopted
Coffin C et al
Simplified care: No treatment co-pays
Partially Adopted
Coffin C et al
Adult HBV vaccination policy for high-risk populations
Adopted
National Advisory Committee on Immunization
Public budget line for testing and treatment
Adopted
Pan American Health Organization and WHO
HCV National Action Plan
Source:
HCV elimination goal
Source:
Year of HCV elimination goal
2030
Source:
National prevalence survey within the last 5 years
Not Adopted
Estimates of economic burden
Adopted
Myers RP et al
System for monitoring testing and treatment
Not Adopted
Pearce ME et al
Recommendations for HCV testing of pregnant women
Partially Adopted
Pearce ME et al
Registration of originator HCV DAAs
Adopted
Government of Canada
Eligible for HCV generic medicines
No
Licensed point-of-care PCR testing to detect HCV
Not Adopted
Health Canada
HCV testing policy
Risk-based
Grad R et al
National treatment guidelines exist
Adopted
Shah, H et al
Simplified care: Non-specialists can prescribe treatment
Not Adopted
van Buuren N et al
Simplified care: No treatment co-pays
Partially Adopted
No fibrosis restrictions
Partially Adopted
Action Hepatitis Canada
No sobriety restrictions
Adopted
Action Hepatitis Canada
National policy for harm reduction for persons who inject drugs
Adopted
Georgetown HIV Policy Lab
At least one needle-syringe exchange program (NSP) operational
Yes
Source: Harm Reduction International
At least one opioid substitution therapy (OST) program operational
Yes
Source: Harm Reduction International
OST in at least one prison
Yes
Source: Harm Reduction International
Decriminalization of possession of syringes and paraphernalia
Adopted
Georgetown HIV Policy Lab
Public budget line for testing and treatment
Adopted
Pan American Health Organization and WHO

Hepatitis C

Download HCV data

Prevalence of chronic HCV (RNA+/cAg)

National
Download
Value (%) Year Type Source
0.6 (0.40 - 0.70) 2015 Modelled Blach et al, 2017
0.8 (0.50 - 1) 2014 Modelled Gower et al, 2014
1 (0.81 - 1.21) 2019 Modelled IHME, GBD 2019 (accessed 2022)
1.01 (0.83 - 1.22) 2018 Modelled IHME, GBD 2019 (accessed 2022)
1.01 (0.83 - 1.22) 2017 Modelled IHME, GBD 2019 (accessed 2022)
0.99 (0.81 - 1.19) 2016 Modelled IHME, GBD 2019 (accessed 2022)
0.96 (0.78 - 1.17) 2015 Modelled IHME, GBD 2019 (accessed 2022)
0.96 (0.78 - 1.17) 2014 Modelled IHME, GBD 2019 (accessed 2022)
0.96 (0.79 - 1.16) 2013 Modelled IHME, GBD 2019 (accessed 2022)
0.97 (0.79 - 1.17) 2012 Modelled IHME, GBD 2019 (accessed 2022)
0.97 (0.79 - 1.17) 2011 Modelled IHME, GBD 2019 (accessed 2022)
0.96 (0.79 - 1.17) 2010 Modelled IHME, GBD 2019 (accessed 2022)
0.95 (0.78 - 1.15) 2009 Modelled IHME, GBD 2019 (accessed 2022)
0.92 (0.76 - 1.12) 2008 Modelled IHME, GBD 2019 (accessed 2022)
0.89 (0.73 - 1.07) 2007 Modelled IHME, GBD 2019 (accessed 2022)
0.86 (0.71 - 1.04) 2006 Modelled IHME, GBD 2019 (accessed 2022)
0.85 (0.70 - 1.02) 2005 Modelled IHME, GBD 2019 (accessed 2022)
0.84 (0.70 - 1.02) 2004 Modelled IHME, GBD 2019 (accessed 2022)
0.85 (0.70 - 1.03) 2003 Modelled IHME, GBD 2019 (accessed 2022)
0.86 (0.71 - 1.04) 2002 Modelled IHME, GBD 2019 (accessed 2022)
0.86 (0.71 - 1.06) 2001 Modelled IHME, GBD 2019 (accessed 2022)
0.87 (0.71 - 1.06) 2000 Modelled IHME, GBD 2019 (accessed 2022)
0.87 (0.71 - 1.05) 1999 Modelled IHME, GBD 2019 (accessed 2022)
0.87 (0.71 - 1.05) 1998 Modelled IHME, GBD 2019 (accessed 2022)
0.87 (0.71 - 1.05) 1997 Modelled IHME, GBD 2019 (accessed 2022)
0.87 (0.71 - 1.04) 1996 Modelled IHME, GBD 2019 (accessed 2022)
0.86 (0.70 - 1.04) 1995 Modelled IHME, GBD 2019 (accessed 2022)
0.86 (0.70 - 1.04) 1994 Modelled IHME, GBD 2019 (accessed 2022)
0.87 (0.70 - 1.04) 1993 Modelled IHME, GBD 2019 (accessed 2022)
0.87 (0.71 - 1.05) 1992 Modelled IHME, GBD 2019 (accessed 2022)
0.87 (0.71 - 1.06) 1991 Modelled IHME, GBD 2019 (accessed 2022)
0.88 (0.71 - 1.07) 1990 Modelled IHME, GBD 2019 (accessed 2022)
0.93 (0.75 - 1.13) 2019 Modelled IHME, GBD 2019 (accessed 2020)
Showing out of
Show more
Women of childbearing age (15–49 years)
Download
Value (%) Year Type Source
0.35 (0.22 - 0.40) 2019 Modelled Dugan et al., 2021
Technical notes

Prevalence of anti-HCV

National
Download
Value (%) Year Type Source
1.1 (0.60 - 1.30) 2014 Modelled Gower et al, 2014
0.96 2019 Modelled Jin et al. 2017
Showing out of
Show more
Men who have sex with men (MSM) Living with HIV
Download
Value (%) Year Type Source
14.2 (9.30 - 20.10) 2019 Modelled Jin et al. 2017
People who inject drugs (PWID)
Download
Value (%) Year Type Source
70.6 (60.10 - 65.40) 2014 Modelled Degenhardt L et al, 2017
Men who have sex with men (MSM)
Download
Value (%) Year Type Source
5 2019 Modelled Jin et al. 2017
Technical notes

Number of people living with chronic HCV (RNA+/cAg)

National
Download
Value Year Type Source
212,000 (136,000 - 246,000) 2015 Modelled Blach et al, 2017
55,800 2011 Survey/reported Rotermann A et al.
400,000 2013 Survey/reported Dr. Morris Sherman Paper on Liver Disease in Canada Report to the Canadian Liver Foundation for HBV and HCV estimates
221,046 (180,039 - 270,195) 1990 Modelled IHME, GBD 2019 (accessed 2022)
223,486 (182,132 - 271,275) 1991 Modelled IHME, GBD 2019 (accessed 2022)
225,759 (184,000 - 273,334) 1992 Modelled IHME, GBD 2019 (accessed 2022)
227,973 (185,862 - 273,756) 1993 Modelled IHME, GBD 2019 (accessed 2022)
230,267 (186,641 - 276,173) 1994 Modelled IHME, GBD 2019 (accessed 2022)
232,845 (188,502 - 281,058) 1995 Modelled IHME, GBD 2019 (accessed 2022)
235,437 (192,090 - 284,431) 1996 Modelled IHME, GBD 2019 (accessed 2022)
237,785 (194,671 - 287,547) 1997 Modelled IHME, GBD 2019 (accessed 2022)
239,980 (198,085 - 291,576) 1998 Modelled IHME, GBD 2019 (accessed 2022)
242,135 (199,468 - 294,825) 1999 Modelled IHME, GBD 2019 (accessed 2022)
244,411 (201,138 - 299,092) 2000 Modelled IHME, GBD 2019 (accessed 2022)
245,999 (203,023 - 300,748) 2001 Modelled IHME, GBD 2019 (accessed 2022)
246,627 (204,706 - 301,242) 2002 Modelled IHME, GBD 2019 (accessed 2022)
247,115 (204,913 - 300,842) 2003 Modelled IHME, GBD 2019 (accessed 2022)
248,334 (205,444 - 301,219) 2004 Modelled IHME, GBD 2019 (accessed 2022)
251,250 (207,424 - 304,850) 2005 Modelled IHME, GBD 2019 (accessed 2022)
258,466 (213,612 - 312,969) 2006 Modelled IHME, GBD 2019 (accessed 2022)
270,221 (223,532 - 325,409) 2007 Modelled IHME, GBD 2019 (accessed 2022)
283,737 (233,360 - 343,636) 2008 Modelled IHME, GBD 2019 (accessed 2022)
296,088 (241,980 - 357,671) 2009 Modelled IHME, GBD 2019 (accessed 2022)
304,206 (248,086 - 370,310) 2010 Modelled IHME, GBD 2019 (accessed 2022)
308,263 (251,470 - 372,287) 2011 Modelled IHME, GBD 2019 (accessed 2022)
311,066 (254,797 - 375,746) 2012 Modelled IHME, GBD 2019 (accessed 2022)
313,339 (256,756 - 379,820) 2013 Modelled IHME, GBD 2019 (accessed 2022)
315,825 (257,373 - 383,404) 2014 Modelled IHME, GBD 2019 (accessed 2022)
319,373 (260,367 - 389,340) 2015 Modelled IHME, GBD 2019 (accessed 2022)
330,255 (270,068 - 397,684) 2016 Modelled IHME, GBD 2019 (accessed 2022)
341,207 (280,283 - 410,536) 2017 Modelled IHME, GBD 2019 (accessed 2022)
344,296 (284,188 - 414,116) 2018 Modelled IHME, GBD 2019 (accessed 2022)
342,994 (278,359 - 414,066) 2019 Modelled IHME, GBD 2019 (accessed 2022)
340,410 (275,605 - 411,373) 2019 Modelled IHME, GBD 2019 (accessed 2020)
Showing out of
Show more
Women of childbearing age (15–49 years)
Download
Value Year Type Source
29,500 (18,900 - 34,100) 2019 Modelled Dugan et al., 2021

Number of new cases of HCV

National
Download
Value Year Type Source
12,447 2018 Survey/reported Public Health Agency of Canada: Surveillance Report 2018

HCV-related death rate

National
Download
Value (Deaths per 100,000) Year Type Source
7.37 (5.81 - 9.07) 2019 Modelled IHME, GBD 2019 (accessed 2020)
5.19 (4.16 - 6.33) 1990 Modelled IHME, GBD 2019 (accessed 2022)
5.18 (4.13 - 6.29) 1991 Modelled IHME, GBD 2019 (accessed 2022)
5.19 (4.13 - 6.32) 1992 Modelled IHME, GBD 2019 (accessed 2022)
5.29 (4.22 - 6.43) 1993 Modelled IHME, GBD 2019 (accessed 2022)
5.33 (4.25 - 6.47) 1994 Modelled IHME, GBD 2019 (accessed 2022)
5.37 (4.27 - 6.51) 1995 Modelled IHME, GBD 2019 (accessed 2022)
5.38 (4.30 - 6.52) 1996 Modelled IHME, GBD 2019 (accessed 2022)
5.4 (4.34 - 6.55) 1997 Modelled IHME, GBD 2019 (accessed 2022)
5.5 (4.43 - 6.68) 1998 Modelled IHME, GBD 2019 (accessed 2022)
5.53 (4.44 - 6.73) 1999 Modelled IHME, GBD 2019 (accessed 2022)
5.55 (4.46 - 6.75) 2000 Modelled IHME, GBD 2019 (accessed 2022)
5.72 (4.62 - 7.03) 2002 Modelled IHME, GBD 2019 (accessed 2022)
5.62 (4.55 - 6.90) 2001 Modelled IHME, GBD 2019 (accessed 2022)
5.77 (4.66 - 7.11) 2003 Modelled IHME, GBD 2019 (accessed 2022)
5.76 (4.62 - 7.08) 2004 Modelled IHME, GBD 2019 (accessed 2022)
5.87 (4.71 - 7.20) 2005 Modelled IHME, GBD 2019 (accessed 2022)
5.92 (4.75 - 7.24) 2006 Modelled IHME, GBD 2019 (accessed 2022)
6.12 (4.91 - 7.46) 2007 Modelled IHME, GBD 2019 (accessed 2022)
6.25 (5.06 - 7.60) 2008 Modelled IHME, GBD 2019 (accessed 2022)
6.43 (5.17 - 7.77) 2010 Modelled IHME, GBD 2019 (accessed 2022)
6.32 (5.10 - 7.65) 2009 Modelled IHME, GBD 2019 (accessed 2022)
6.51 (5.19 - 7.85) 2011 Modelled IHME, GBD 2019 (accessed 2022)
6.69 (5.33 - 8.07) 2012 Modelled IHME, GBD 2019 (accessed 2022)
6.84 (5.45 - 8.23) 2013 Modelled IHME, GBD 2019 (accessed 2022)
7.01 (5.58 - 8.45) 2014 Modelled IHME, GBD 2019 (accessed 2022)
7.1 (5.62 - 8.59) 2015 Modelled IHME, GBD 2019 (accessed 2022)
7.08 (5.60 - 8.60) 2016 Modelled IHME, GBD 2019 (accessed 2022)
7.07 (5.60 - 8.63) 2017 Modelled IHME, GBD 2019 (accessed 2022)
7.27 (5.75 - 8.90) 2018 Modelled IHME, GBD 2019 (accessed 2022)
7.37 (5.81 - 9.07) 2019 Modelled IHME, GBD 2019 (accessed 2022)
Showing out of
Show more
Technical notes

HCV-related deaths

National
Download
Value Year Type Source
1,941 2016 Modelled WHO
2,692 (2,122 - 3,311) 2019 Modelled IHME, GBD 2019 (accessed 2022)
2,692 (2,122 - 3,311) 2019 Modelled IHME, GBD 2019 (accessed 2020)
2,636 (2,085 - 3,227) 2018 Modelled IHME, GBD 2019 (accessed 2022)
2,543 (2,015 - 3,105) 2017 Modelled IHME, GBD 2019 (accessed 2022)
2,525 (1,999 - 3,066) 2016 Modelled IHME, GBD 2019 (accessed 2022)
2,509 (1,987 - 3,039) 2015 Modelled IHME, GBD 2019 (accessed 2022)
2,453 (1,955 - 2,958) 2014 Modelled IHME, GBD 2019 (accessed 2022)
2,370 (1,890 - 2,855) 2013 Modelled IHME, GBD 2019 (accessed 2022)
2,296 (1,828 - 2,769) 2012 Modelled IHME, GBD 2019 (accessed 2022)
2,209 (1,761 - 2,664) 2011 Modelled IHME, GBD 2019 (accessed 2022)
2,159 (1,737 - 2,610) 2010 Modelled IHME, GBD 2019 (accessed 2022)
2,100 (1,692 - 2,541) 2009 Modelled IHME, GBD 2019 (accessed 2022)
2,051 (1,660 - 2,495) 2008 Modelled IHME, GBD 2019 (accessed 2022)
1,987 (1,594 - 2,420) 2007 Modelled IHME, GBD 2019 (accessed 2022)
1,900 (1,524 - 2,322) 2006 Modelled IHME, GBD 2019 (accessed 2022)
1,864 (1,496 - 2,286) 2005 Modelled IHME, GBD 2019 (accessed 2022)
1,808 (1,451 - 2,224) 2004 Modelled IHME, GBD 2019 (accessed 2022)
1,796 (1,450 - 2,211) 2003 Modelled IHME, GBD 2019 (accessed 2022)
1,763 (1,424 - 2,168) 2002 Modelled IHME, GBD 2019 (accessed 2022)
1,717 (1,389 - 2,107) 2001 Modelled IHME, GBD 2019 (accessed 2022)
1,682 (1,353 - 2,047) 2000 Modelled IHME, GBD 2019 (accessed 2022)
1,662 (1,336 - 2,022) 1999 Modelled IHME, GBD 2019 (accessed 2022)
1,640 (1,320 - 1,992) 1998 Modelled IHME, GBD 2019 (accessed 2022)
1,598 (1,283 - 1,936) 1997 Modelled IHME, GBD 2019 (accessed 2022)
1,577 (1,262 - 1,911) 1996 Modelled IHME, GBD 2019 (accessed 2022)
1,560 (1,239 - 1,891) 1995 Modelled IHME, GBD 2019 (accessed 2022)
1,530 (1,220 - 1,858) 1994 Modelled IHME, GBD 2019 (accessed 2022)
1,502 (1,197 - 1,825) 1993 Modelled IHME, GBD 2019 (accessed 2022)
1,455 (1,159 - 1,772) 1992 Modelled IHME, GBD 2019 (accessed 2022)
1,433 (1,142 - 1,741) 1991 Modelled IHME, GBD 2019 (accessed 2022)
1,416 (1,134 - 1,727) 1990 Modelled IHME, GBD 2019 (accessed 2022)
Showing out of
Show more
Technical notes

Percent of liver cancer deaths attributable to HCV

National
Download
Value (%) Year Type Source
6 (4 - 8) 1990 Modelled IHME, GBD 2019 (accessed 2022)
6 (4 - 8) 1991 Modelled IHME, GBD 2019 (accessed 2022)
6 (4 - 9) 1992 Modelled IHME, GBD 2019 (accessed 2022)
7 (5 - 9) 1993 Modelled IHME, GBD 2019 (accessed 2022)
7 (5 - 9) 1994 Modelled IHME, GBD 2019 (accessed 2022)
7 (5 - 10) 1995 Modelled IHME, GBD 2019 (accessed 2022)
8 (5 - 10) 1996 Modelled IHME, GBD 2019 (accessed 2022)
8 (6 - 11) 1997 Modelled IHME, GBD 2019 (accessed 2022)
9 (6 - 12) 1999 Modelled IHME, GBD 2019 (accessed 2022)
9 (6 - 12) 1998 Modelled IHME, GBD 2019 (accessed 2022)
10 (7 - 13) 2000 Modelled IHME, GBD 2019 (accessed 2022)
10 (7 - 13) 2001 Modelled IHME, GBD 2019 (accessed 2022)
10 (7 - 14) 2004 Modelled IHME, GBD 2019 (accessed 2022)
10 (7 - 13) 2003 Modelled IHME, GBD 2019 (accessed 2022)
10 (7 - 13) 2002 Modelled IHME, GBD 2019 (accessed 2022)
11 (8 - 15) 2005 Modelled IHME, GBD 2019 (accessed 2022)
12 (8 - 16) 2006 Modelled IHME, GBD 2019 (accessed 2022)
13 (9 - 18) 2007 Modelled IHME, GBD 2019 (accessed 2022)
14 (10 - 19) 2008 Modelled IHME, GBD 2019 (accessed 2022)
16 (11 - 22) 2010 Modelled IHME, GBD 2019 (accessed 2022)
15 (11 - 20) 2009 Modelled IHME, GBD 2019 (accessed 2022)
18 (13 - 24) 2012 Modelled IHME, GBD 2019 (accessed 2022)
17 (12 - 23) 2011 Modelled IHME, GBD 2019 (accessed 2022)
19 (13 - 25) 2013 Modelled IHME, GBD 2019 (accessed 2022)
19 (13 - 26) 2014 Modelled IHME, GBD 2019 (accessed 2022)
19 (13 - 25) 2016 Modelled IHME, GBD 2019 (accessed 2022)
18 (13 - 25) 2017 Modelled IHME, GBD 2019 (accessed 2022)
19 (14 - 26) 2015 Modelled IHME, GBD 2019 (accessed 2022)
18 (12 - 25) 2018 Modelled IHME, GBD 2019 (accessed 2022)
18 (12 - 26) 2019 Modelled IHME, GBD 2019 (accessed 2022)
20 (14 - 26) 2019 Modelled IHME, GBD 2019 (accessed 2020)
Showing out of
Show more
Technical notes

Number of persons treated for HCV

National
Download
Value Year Type Source
12,718 2016 Survey/reported Action Hepatitis Canada. Progress Towards Viral Hepatitis Elimination By 2030 In Canada: 2021 Report
14,520 2017 Survey/reported Action Hepatitis Canada. Progress Towards Viral Hepatitis Elimination By 2030 In Canada: 2021 Report
17,973 2018 Survey/reported Action Hepatitis Canada. Progress Towards Viral Hepatitis Elimination By 2030 In Canada: 2021 Report
16,493 2019 Survey/reported Action Hepatitis Canada. Progress Towards Viral Hepatitis Elimination By 2030 In Canada: 2021 Report
11,331 2020 Survey/reported Action Hepatitis Canada. Progress Towards Viral Hepatitis Elimination By 2030 In Canada: 2021 Report
Showing out of
Show more
Technical notes

Number of needles/syringes per PWID per year

National
Download
Value Year Type Source
261 (136 - 883) 2016 Survey/reported The Canadian Network on Hepatitis C Blueprint Writing Committee and Working Groups
People who inject drugs (PWID)
Download
Value Year Type Source
148 (129 - 174) 2015 Survey/reported Larney S et al, 2017
Technical notes

Proportion of persons living with HCV diagnosed

National
Download
Value (%) Year Type Source
56 2016 Modelled CATIE: The epidemiology of hepatitis C in Canada
HBV National Action Plan
Source:
HBV elimination goal
Source:
Year of HBV elimination goal
2030
Source:
National prevalence survey within the last 5 years
Not Adopted
Estimates of economic burden
Adopted
Tian F et al
System for monitoring testing and treatment
Not Adopted
Georgetown HIV Policy Lab
HepB birth dose policy
Partially Adopted
Coffin CS, et al
Recommendations for HBV testing of pregnant women
Adopted
National Advisory Committee on Immunization
Eligible for HBV generic medicines
Licensed point-of-care PCR testing to detect HBV
Not Adopted
Health Canada
HBV testing policy
Risk-based
Coffin C et al
HBV testing recommendations for key population (i.e. migrants, foreign-born, etc)
Adopted
Coffin C et al
National treatment guidelines exist
Adopted
Coffin C et al
Simplified care: No treatment co-pays
Partially Adopted
Coffin C et al
Adult HBV vaccination policy for high-risk populations
Adopted
National Advisory Committee on Immunization
Public budget line for testing and treatment
Adopted
Pan American Health Organization and WHO
HCV National Action Plan
Source:
HCV elimination goal
Source:
Year of HCV elimination goal
2030
Source:
National prevalence survey within the last 5 years
Not Adopted
Estimates of economic burden
Adopted
Myers RP et al
System for monitoring testing and treatment
Not Adopted
Pearce ME et al
Recommendations for HCV testing of pregnant women
Partially Adopted
Pearce ME et al
Registration of originator HCV DAAs
Adopted
Government of Canada
Eligible for HCV generic medicines
No
Licensed point-of-care PCR testing to detect HCV
Not Adopted
Health Canada
HCV testing policy
Risk-based
Grad R et al
National treatment guidelines exist
Adopted
Shah, H et al
Simplified care: Non-specialists can prescribe treatment
Not Adopted
van Buuren N et al
Simplified care: No treatment co-pays
Partially Adopted
No fibrosis restrictions
Partially Adopted
Action Hepatitis Canada
No sobriety restrictions
Adopted
Action Hepatitis Canada
National policy for harm reduction for persons who inject drugs
Adopted
Georgetown HIV Policy Lab
At least one needle-syringe exchange program (NSP) operational
Yes
Source: Harm Reduction International
At least one opioid substitution therapy (OST) program operational
Yes
Source: Harm Reduction International
OST in at least one prison
Yes
Source: Harm Reduction International
Decriminalization of possession of syringes and paraphernalia
Adopted
Georgetown HIV Policy Lab
Public budget line for testing and treatment
Adopted
Pan American Health Organization and WHO

Overview

HBV elimination goal
Year of goal
2030
HCV elimination goal
Year of goal
2030

Prevalence (national)

Modelled

HBV (HBsAg+)
1.71 (%)
2019
(1.57 - 1.87(%))
IHME, GBD 2019 (accessed 2020)
HCV (RNA/cAg+)
0.93 (%)
2019
(0.75 - 1.13(%))
IHME, GBD 2019 (accessed 2020)

Survey/surveillance

No data available
No data available

Hepatitis related deaths (national)

Modelled

HBV
445
2019
(332 - 575)
IHME, GBD 2019 (accessed 2022)

Survey/surveillance

No data available
HBV chart

Modelled

HCV
2,692
2019
(2,122 - 3,311)
IHME, GBD 2019 (accessed 2022)

Survey/surveillance

No data available
HCV chart

Prevalence < 5

HBV
0.34 (%)
2020, latest modelled
(0.29 - 0.39(%))
WHO

Prevalence PWID

HCV
70.60 (%)
2014, latest modelled
(60.10 - 65.40(%))
Degenhardt L et al, 2017

Birth dose vaccination coverage (national)

Survey/surveillance

No data available

No. of syringes/PWID/year

Survey/surveillance

HCV
148
2015
(129 - 174)
Larney S et al, 2017
Eligible for HBV generic medicines
Eligible for HCV generic medicines
No
Download National Hepatitis Elimination Profile (N-HEP)

Latest news

View all

Action plan

View all

Elimination champion

News

Action plans

Resources

Programs

Partners